Protalix BioTherapeutics (PLX) Non-Current Deferred Tax Liability (2022 - 2025)
Protalix BioTherapeutics (PLX) posted quarterly Non-Current Deferred Tax Liability of $14.6 million for Q4 2025, up 22.69% year-over-year from $11.9 million in Q4 2024, and up 22.69% quarter-over-quarter from $11.9 million in Q4 2024.
Protalix BioTherapeutics (PLX) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends
Protalix BioTherapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $14.6 million for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 22.69% year-over-year to $14.6 million; the TTM figure through Dec 2025 stood at $14.6 million (up 22.69% YoY), while the FY2025 annual figure was $14.6 million, up 22.69% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $14.6 million, up from $11.9 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $28.5 million in Q4 2022, with the low at $11.9 million in Q4 2024.
- The 4-year median for Non-Current Deferred Tax Liability is $14.5 million (2023), against an average of $17.3 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability plunged 49.47% in 2023, then rose 22.69% in 2025.
- Protalix BioTherapeutics' Non-Current Deferred Tax Liability stood at $28.5 million in 2022, then slumped by 49.47% to $14.4 million in 2023, then declined by 17.36% to $11.9 million in 2024, then rose by 22.69% to $14.6 million in 2025.
- Business Quant data shows PLX's Non-Current Deferred Tax Liability at $14.6 million in Q4 2025, $11.9 million in Q4 2024, and $14.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.60 Mn |
| Dec 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 11.90 Mn |
| Dec 31, 2024 | 11.90 Mn |
| Dec 31, 2023 | 14.40 Mn |
| Dec 31, 2023 | 14.40 Mn |
| Dec 31, 2022 | 28.50 Mn |
| Dec 31, 2022 | 28.50 Mn |